Roche‘s (OTC:RHHBY) Genentech reported this week that the company launched three Phase III trials evaluating the Port drug-delivery implant in patients with wet age-related macular degeneration and diabetic macular edema.
The device is a refillable eye implant designed to continuously release drugs over a period of several months.
Get the full story at our sister site, Drug Delivery Business News.